Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
★★★★★ TopFund est.
TopFund Score (fallback rating)
- Calculated by: TopFund — used only when no third-party rating exists for this fund
- Formula: 3-year trailing return percentile within category, adjusted ±1 star for expense ratio
- Refresh frequency: Whenever TopFund re-syncs this fund's data
- Limitations: A simplified 2-factor estimate, not equivalent to a rating agency's full analysis
TopFund Score: 70/100 · Good
How this score is calculated
- Star rating (35%)4/5
- 3Y CAGR (30%)—
- Expense ratio (20%)1.1%
- AUM (15%)₹825 Cr
Not investment advice — an analytical read of public fund data. Methodology →
WhiteOak Capital Mutual Fund · Equity · Sectoral
₹17.68
AUM: ₹824 Cr
NAV updated 21 days ago
Plan
Direct
Option
Growth
Risk
Very High
Expense Ratio
1.1%
Exit Load
Nil
Fund Manager
Ashish Agrawal
Inception
Feb 2024
Benchmark
BSE Healthcare Total Return Index
Sharpe Ratio
1.82
Std Dev (1Y)
12.88%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
+1.21%
3m
+12.21%
6m
+23.35%
1y
+22.99%
3y
—
5y
—
10y
—
since inception
+24.33%
TopFund's Take on WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth holds up reasonably well within the Sectoral category, backed by a 4-star rating. Recent 1-year performance has been notably strong, though momentum like this doesn't always hold over longer periods. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 70/100.
Cost: At 1.1%, the expense ratio runs 11% above the Sectoral category average of 0.99%. That gap is worth weighing against the fund's actual performance versus cheaper peers before committing to a long SIP.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a strong Sharpe ratio of 1.82 — the fund has generated solid returns relative to the volatility it exposed investors to. Separately, annualised volatility of 12.88% is fairly typical for Sectoral funds.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
Sector Allocation
Asset Allocation
Fund Snapshot
Similar Funds
DSP Nifty Healthcare Index Fund - Direct- Growth
DSP Mutual Fund
quant BFSI Fund - Growth Option - Direct Plan
Quant Mutual Fund
DSP Nifty Bank Index Fund - Direct - Growth
DSP Mutual Fund
Invesco India Financial Services Fund - Direct Plan - Growth
Invesco Mutual Fund
BANK OF INDIA Manufacturing & Infrastructure Fund-Direct Plan-Growth
Bank of India Mutual Fund
Bandhan BSE Healthcare Index Fund Direct Plan - Growth
Bandhan Mutual Fund
Tools & Guides for This Fund
Frequently Asked Questions about WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth
The current NAV (Net Asset Value) of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is ₹17.68. NAV is updated every business day after market close by AMFI.
1Y: 22.99%
The expense ratio of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is 1.1% per annum. This is the annual fee charged by the fund to manage your investment.
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is managed by Ashish Agrawal at WhiteOak Capital Mutual Fund.
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is classified as a Very High risk fund. It is suitable for aggressive investors with a long-term horizon of 5+ years.
WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is a Sectoral fund. SIP suitability depends on your investment goal and risk profile.
You can start a SIP in WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth with as little as ₹500 per month through most mutual fund platforms. The minimum lump sum investment is typically ₹1,000.
The Assets Under Management (AUM) of WhiteOak Capital Pharma and Heathcare Fund Direct Plan Growth is ₹825 crore. AUM indicates the total market value of assets managed by the fund.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.
Discussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.